<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04709770</url>
  </required_header>
  <id_info>
    <org_study_id>Policlinic Hospital 7</org_study_id>
    <nct_id>NCT04709770</nct_id>
  </id_info>
  <brief_title>Low-volume vs High-volume Polyethylene Glycol Based Bowel Preparation for Colonoscopy in People Receiving Hemodialysis</brief_title>
  <acronym>PrepDial</acronym>
  <official_title>Comparison of Low-volume Versus High-volume Polyethylene Glycol Based Bowel Preparation for Colonoscopy in People Receiving Hemodialysis: a Randomized Non-inferiority Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alfredo Di Leo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Alfasigma S.p.A.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Bari</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Current American Society for Gastrointestinal Endoscopy (ASGE) and European Society of&#xD;
      Gastrointestinal Endoscopy (ESGE) guidelines recommend a split regimen of high-volume&#xD;
      (4-liter polyethylene glycol-based preparation) or low-volume (2-liter polyethylene&#xD;
      glycol-based solutions or sodium picosulphate plus magnesium citrate) formulations for&#xD;
      routine bowel preparation.&#xD;
&#xD;
      Some concerns have been raised about the use of oral bowel-cleansing agents in people&#xD;
      receiving hemodialysis due to the possibility of secondary intravascular depletion. There is&#xD;
      a risk for thrombosis of dialysis access in case of hypotension. The association of&#xD;
      hemodialysis treatment and the use of bowel preparations may induce severe hypovolaemia.&#xD;
      Finally, the 4-liter intake with high-volume preparations may cause fluid overload in anuric&#xD;
      patients.&#xD;
&#xD;
      The aim of our study will be to assess in a randomized trial the non-inferiority of a&#xD;
      low-volume versus a high-volume polyethylene glycol-based bowel preparation for adequate&#xD;
      bowel cleansing in people receiving hemodialysis (primary end-point). We will also compare&#xD;
      the low-volume versus the high-volume preparation for other endoscopic and nephrologic&#xD;
      relevant clinical outcomes (secondary end-points).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study design:&#xD;
&#xD;
      This will be a multicentre, outcome assessor-blinded, parallel-arm, centrally randomized,&#xD;
      non-inferiority trial. Randomization will be performed centrally by the coordinating center.&#xD;
&#xD;
      Consecutive inpatients and outpatients on hemodialysis with an indication to undergo&#xD;
      colonoscopy (positive fecal occult blood test or fecal immunochemical test, signs or symptoms&#xD;
      of colorectal disease, colorectal cancer screening, colorectal cancer surveillance,&#xD;
      inflammatory bowel diseases, or inclusion in kidney transplantation waiting list) will be&#xD;
      screened for inclusion in the trial.&#xD;
&#xD;
      At enrolment visit, eligible subjects will be allocated to either the low-volume or&#xD;
      high-volume bowel preparation group (ratio 1:1). Participants in the low-volume group will&#xD;
      receive the formulation of 2-liters polyethylene glycol with citrate and simethicone&#xD;
      (Clensia, Alfasigma S.p.A., Milan, Italy), while those in the high-volume arm will receive&#xD;
      4-liters polyethylene glycol with simethicone (Selg Esse, Alfasigma S.p.A., Milan, Italy).&#xD;
      Participants in both groups will be prescribed a low residue diet for 3 days before&#xD;
      colonoscopy and will be instructed to take the bowel cleansing agents as split dose, taking&#xD;
      the first half of solution the evening before the endoscopic examination and the second in&#xD;
      the morning of the day of the procedure. To improve compliance, participants will also&#xD;
      receive a booklet in plain language to explain the details of low residue diet and modality&#xD;
      of bowel preparation intake.&#xD;
&#xD;
      All endoscopic examinations will be scheduled on days free from dialysis sessions between 2&#xD;
      and 5 hours after the end of the administration of the last dose of preparation. On the day&#xD;
      of the colonoscopy, all participants will fill in a questionnaire to measure participants'&#xD;
      compliance, tolerability, and willingness to repeat the preparation they have been allocated&#xD;
      to. Participants will be aware of the bowel preparation they received. On the opposite,&#xD;
      endoscopists and nephrologists measuring primary and secondary outcomes (i.e. outcome&#xD;
      assessors) will be blinded to the arm each subject has been allocated to and instructed to&#xD;
      avoid any discussion with participants that could reveal the type of bowel cleansing agent.&#xD;
&#xD;
      Recruitment will last 12 months and follow-up will be completed 1 month after the last&#xD;
      participant undergoes colonoscopy.&#xD;
&#xD;
      Before randomization and during the one-month follow-up, participants will receive (in a&#xD;
      non-randomized fashion) all relevant co-interventions (e.g. iron, lipid-lowering agents, bone&#xD;
      disease agents, antihypertensive agents, etc.), which are peculiar of standard hemodialysis&#xD;
      treatment, as per their usual attending physician's practice to achieve and maintain standard&#xD;
      hemodialysis clinical performance measures.&#xD;
&#xD;
      At the time of enrolment and colonoscopy scheduled simple trial follow-up visits will be&#xD;
      performed. All clinical events following the endoscopic procedure will be measured during the&#xD;
      one-month follow-up period.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">February 1, 2021</start_date>
  <completion_date type="Anticipated">March 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">March 1, 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adequate bowel preparation</measure>
    <time_frame>During colonoscopy</time_frame>
    <description>Proportion of participants with Boston Bowel Preparation Scale ≥6 with each segmental score ≥2</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adenoma detection rate</measure>
    <time_frame>During colonoscopy</time_frame>
    <description>Proportion of patients with at least one adenoma</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cecal intubation rate</measure>
    <time_frame>During colonoscopy</time_frame>
    <description>Proportion of endoscopic examinations reaching the cecum</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participants' compliance</measure>
    <time_frame>During colonoscopy</time_frame>
    <description>Proportion of participants with intake of at least 75 percent of the bowel preparation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participants' tolerability</measure>
    <time_frame>During colonoscopy</time_frame>
    <description>Proportion of participants presenting nausea, bloating, vomiting, abdominal pain, and/or anal irritation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Willingness to repeat the preparation</measure>
    <time_frame>During colonoscopy</time_frame>
    <description>Proportion of participants willing to use the same bowel preparation for future examinations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>During colonoscopy and the first hemodialysis session following colonoscopy</time_frame>
    <description>Proportion of participants with any adverse event occurred during the intake of bowel preparation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All-cause hospitalization</measure>
    <time_frame>Within a 30-day period</time_frame>
    <description>Proportion of participants hospitalized after bowel preparation intake for any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All-cause mortality</measure>
    <time_frame>Within a 30-day period</time_frame>
    <description>Proportion of participants who died after bowel preparation intake for any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Emergency hemodialysis sessions</measure>
    <time_frame>Within a 30-day period</time_frame>
    <description>Proportion of participants needing additional hemodialysis sessions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiovascular events</measure>
    <time_frame>Within a 30-day period</time_frame>
    <description>Proportion of participants with cardiovascular events (i.e. nonfatal myocardial infarction, acute coronary syndrome, and/or heart failure)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Interdialytic body weight gain</measure>
    <time_frame>During the hemodialysis session preceding and the one following the intake of bowel preparation</time_frame>
    <description>Mean increase in body weight from the hemodialysis session preceding the intake of bowel preparation to the one following the colonoscopy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Variations in serum-electrolyte levels</measure>
    <time_frame>During the hemodialysis session preceding and the one following the intake of bowel preparation</time_frame>
    <description>Mean variation in serum-electrolyte levels between the hemodialysis session preceding and following the intake of bowel preparation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systolic blood pressure</measure>
    <time_frame>During the hemodialysis session preceding and the one following the intake of bowel preparation</time_frame>
    <description>Mean variation in systolic blood pressure between the hemodialysis session preceding and following the intake of bowel preparation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diastolic blood pressure</measure>
    <time_frame>During the hemodialysis session preceding and the one following the intake of bowel preparation</time_frame>
    <description>Mean variation in diastolic blood pressure between the hemodialysis session preceding and following the intake of bowel preparation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood flow on dialysis</measure>
    <time_frame>During the hemodialysis session preceding and the one following the intake of bowel preparation</time_frame>
    <description>Mean variation in blood flow on dialysis between the hemodialysis session preceding and following the intake of bowel preparation</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">264</enrollment>
  <condition>Chronic Kidney Diseases</condition>
  <condition>Colon Polyp</condition>
  <condition>Dialysis; Complications</condition>
  <condition>Colon Cancer</condition>
  <arm_group>
    <arm_group_label>Low-volume preparation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Low-volume preparation of 2-liters polyethylene glycol with citrate and simethicone. This formulation includes 4 large (A) and 4 small (B) sachets; the components of 2 sachets A and 2 sachets B are mixed in 1 liter of water.&#xD;
Each sachet A contains:&#xD;
polyethylene glycol (4000) 52.50 g;&#xD;
simethicone 0.08 g;&#xD;
sodium sulphate anhydrous 3.75 g.&#xD;
Each sachet B contains:&#xD;
sodium citrate 1.863 g;&#xD;
anhydrous citric acid 0.813 g;&#xD;
sodium chloride 0.73 g;&#xD;
potassium chloride: 0.37 g;&#xD;
acesulfame potassium 0.13 g. Participants will drink the first liter of preparation at 19.00 p.m. on the day before the colonoscopy, at a rate of 250 ml every 15 minutes, followed by 500 ml of clear liquids. The second liter of preparation will be administered at 7.00 a.m. on the day of the colonoscopy, at a rate of 250 ml every 15 minutes, followed by 500 ml of clear liquids.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High-volume preparation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>High-volume preparation with 4-liters polyethyleneglycol with simethicone. This formulation includes 4 sachets, each dissolved in 1 liter of water.&#xD;
Each sachet contains:&#xD;
polyethylene glycol (4000) 58.30 g;&#xD;
simethicone 0.08 g;&#xD;
sodium sulphate anhydrous 5.68 g;&#xD;
sodium bicarbonate 1.68 g;&#xD;
sodium chloride 1.46 g;&#xD;
potassium chloride 0.74 g. Participants will drink the first 2 liters of preparation at 19.00 p.m. on the day before colonoscopy, at a rate of 250 ml every 15 minutes. The remaining 2 liters of preparation will be administered at 6.00 a.m. on the day of the endoscopic procedure, at a rate of 250 ml every 15 minutes.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>2-liters polyethylene glycol with citrate and simethicone</intervention_name>
    <description>Low-volume polyethylene glycol-based bowel cleansing agent for colonoscopy.</description>
    <arm_group_label>Low-volume preparation</arm_group_label>
    <other_name>Clensia</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>4-liters polyethylene glycol with simethicone</intervention_name>
    <description>High-volume polyethylene glycol-based bowel cleansing agent for colonoscopy.</description>
    <arm_group_label>High-volume preparation</arm_group_label>
    <other_name>Selg Esse</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Low-residue diet</intervention_name>
    <description>Diet before colonoscopy.</description>
    <arm_group_label>High-volume preparation</arm_group_label>
    <arm_group_label>Low-volume preparation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  prevalent end stage kidney disease on hemodialysis people (on hemodialysis for ≥6&#xD;
             months; either hemodialysis or hemofiltration or hemodiafiltration, received for at&#xD;
             least 3 times/week for a minimum duration of 4 hours per treatment session for a&#xD;
             minimum of 12 hours/week, according to standard practice for quality hemodialysis in&#xD;
             Italy);&#xD;
&#xD;
          -  inpatients and outpatients with an indication to colonoscopy (e.g. positive fecal&#xD;
             occult blood test or fecal immunochemical test, signs or symptoms of colorectal&#xD;
             disease, colorectal cancer screening, colorectal cancer surveillance, inflammatory&#xD;
             bowel diseases, or inclusion in kidney transplantation waiting list);&#xD;
&#xD;
          -  signature of written informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  end stage kidney disease not on hemodialysis (eg. peritoneal dialysis or kidney&#xD;
             transplantation);&#xD;
&#xD;
          -  previous kidney transplantation;&#xD;
&#xD;
          -  need for colonoscopy in emergency;&#xD;
&#xD;
          -  previous colorectal surgery;&#xD;
&#xD;
          -  contraindications to colonoscopy in the opinion of the managing physician;&#xD;
&#xD;
          -  pregnancy or breastfeeding assessed by dedicated pregnancy tests;&#xD;
&#xD;
          -  known or suspected hypersensitivity to any components of preparations.&#xD;
&#xD;
          -  gastrointestinal perforation;&#xD;
&#xD;
          -  toxic megacolon;&#xD;
&#xD;
          -  inflammatory bowel disease (such as rectal ulcerative colitis, Crohn's disease) in&#xD;
             severe acute phase;&#xD;
&#xD;
          -  occlusive, sub-occlusive or stenotic forms of the intestine, gastric stasis, dynamic&#xD;
             ileus, paralytic ileus;&#xD;
&#xD;
          -  severe state of dehydration;&#xD;
&#xD;
          -  phenylketonuria (due to the presence of aspartame);&#xD;
&#xD;
          -  glucose-6-phosphate dehydrogenase deficiency;&#xD;
&#xD;
          -  severe heart failure: New York Heart Association (NYHA) class III-IV;&#xD;
&#xD;
          -  significant alterations of electrolytes, according to the physician's judgment;&#xD;
&#xD;
          -  participation in a clinical study in which an experimental drug was administered&#xD;
             within 30 days or 5 half-lives before the study drug.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alfredo Di Leo, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Bari</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Alfredo Di Leo, MD PhD</last_name>
    <phone>+39 080 5592925</phone>
    <email>alfredo.dileo@uniba.it</email>
  </overall_contact>
  <reference>
    <citation>Luyckx VA, Tonelli M, Stanifer JW. The global burden of kidney disease and the sustainable development goals. Bull World Health Organ. 2018 Jun 1;96(6):414-422D. doi: 10.2471/BLT.17.206441. Epub 2018 Apr 20.</citation>
    <PMID>29904224</PMID>
  </reference>
  <reference>
    <citation>de Jager DJ, Grootendorst DC, Jager KJ, van Dijk PC, Tomas LM, Ansell D, Collart F, Finne P, Heaf JG, De Meester J, Wetzels JF, Rosendaal FR, Dekker FW. Cardiovascular and noncardiovascular mortality among patients starting dialysis. JAMA. 2009 Oct 28;302(16):1782-9. doi: 10.1001/jama.2009.1488.</citation>
    <PMID>19861670</PMID>
  </reference>
  <reference>
    <citation>Komaki Y, Komaki F, Micic D, Ido A, Sakuraba A. Risk of Colorectal Cancer in Chronic Kidney Disease: A Systematic Review and Meta-Analysis. J Clin Gastroenterol. 2018 Oct;52(9):796-804. doi: 10.1097/MCG.0000000000000880.</citation>
    <PMID>28723862</PMID>
  </reference>
  <reference>
    <citation>Williams AW, Dwyer AC, Eddy AA, Fink JC, Jaber BL, Linas SL, Michael B, O'Hare AM, Schaefer HM, Shaffer RN, Trachtman H, Weiner DE, Falk AR; American Society of Nephrology Quality, and Patient Safety Task Force. Critical and honest conversations: the evidence behind the &quot;Choosing Wisely&quot; campaign recommendations by the American Society of Nephrology. Clin J Am Soc Nephrol. 2012 Oct;7(10):1664-72. doi: 10.2215/CJN.04970512. Epub 2012 Sep 13.</citation>
    <PMID>22977214</PMID>
  </reference>
  <reference>
    <citation>Abramowicz D, Cochat P, Claas FH, Heemann U, Pascual J, Dudley C, Harden P, Hourmant M, Maggiore U, Salvadori M, Spasovski G, Squifflet JP, Steiger J, Torres A, Viklicky O, Zeier M, Vanholder R, Van Biesen W, Nagler E. European Renal Best Practice Guideline on kidney donor and recipient evaluation and perioperative care. Nephrol Dial Transplant. 2015 Nov;30(11):1790-7. doi: 10.1093/ndt/gfu216. Epub 2014 Jul 9.</citation>
    <PMID>25007790</PMID>
  </reference>
  <reference>
    <citation>Harewood GC, Sharma VK, de Garmo P. Impact of colonoscopy preparation quality on detection of suspected colonic neoplasia. Gastrointest Endosc. 2003 Jul;58(1):76-9.</citation>
    <PMID>12838225</PMID>
  </reference>
  <reference>
    <citation>Froehlich F, Wietlisbach V, Gonvers JJ, Burnand B, Vader JP. Impact of colonic cleansing on quality and diagnostic yield of colonoscopy: the European Panel of Appropriateness of Gastrointestinal Endoscopy European multicenter study. Gastrointest Endosc. 2005 Mar;61(3):378-84.</citation>
    <PMID>15758907</PMID>
  </reference>
  <reference>
    <citation>Rex DK, Imperiale TF, Latinovich DR, Bratcher LL. Impact of bowel preparation on efficiency and cost of colonoscopy. Am J Gastroenterol. 2002 Jul;97(7):1696-700.</citation>
    <PMID>12135020</PMID>
  </reference>
  <reference>
    <citation>ASGE Standards of Practice Committee, Saltzman JR, Cash BD, Pasha SF, Early DS, Muthusamy VR, Khashab MA, Chathadi KV, Fanelli RD, Chandrasekhara V, Lightdale JR, Fonkalsrud L, Shergill AK, Hwang JH, Decker GA, Jue TL, Sharaf R, Fisher DA, Evans JA, Foley K, Shaukat A, Eloubeidi MA, Faulx AL, Wang A, Acosta RD. Bowel preparation before colonoscopy. Gastrointest Endosc. 2015 Apr;81(4):781-94. doi: 10.1016/j.gie.2014.09.048. Epub 2015 Jan 14.</citation>
    <PMID>25595062</PMID>
  </reference>
  <reference>
    <citation>Hassan C, Bretthauer M, Kaminski MF, Polkowski M, Rembacken B, Saunders B, Benamouzig R, Holme O, Green S, Kuiper T, Marmo R, Omar M, Petruzziello L, Spada C, Zullo A, Dumonceau JM; European Society of Gastrointestinal Endoscopy. Bowel preparation for colonoscopy: European Society of Gastrointestinal Endoscopy (ESGE) guideline. Endoscopy. 2013;45(2):142-50. doi: 10.1055/s-0032-1326186. Epub 2013 Jan 18.</citation>
    <PMID>23335011</PMID>
  </reference>
  <reference>
    <citation>Johnson DA, Barkun AN, Cohen LB, Dominitz JA, Kaltenbach T, Martel M, Robertson DJ, Boland CR, Giardello FM, Lieberman DA, Levin TR, Rex DK; US Multi-Society Task Force on Colorectal Cancer. Optimizing adequacy of bowel cleansing for colonoscopy: recommendations from the US multi-society task force on colorectal cancer. Gastroenterology. 2014 Oct;147(4):903-24. doi: 10.1053/j.gastro.2014.07.002. Review.</citation>
    <PMID>25239068</PMID>
  </reference>
  <reference>
    <citation>Connor A, Tolan D, Hughes S, Carr N, Tomson C. Consensus guidelines for the safe prescription and administration of oral bowel-cleansing agents. Gut. 2012 Nov;61(11):1525-32. Epub 2012 Jul 26.</citation>
    <PMID>22842619</PMID>
  </reference>
  <reference>
    <citation>Lai EJ, Calderwood AH, Doros G, Fix OK, Jacobson BC. The Boston bowel preparation scale: a valid and reliable instrument for colonoscopy-oriented research. Gastrointest Endosc. 2009 Mar;69(3 Pt 2):620-5. doi: 10.1016/j.gie.2008.05.057. Epub 2009 Jan 10.</citation>
    <PMID>19136102</PMID>
  </reference>
  <reference>
    <citation>Mahmood S, Farooqui SM, Madhoun MF. Predictors of inadequate bowel preparation for colonoscopy: a systematic review and meta-analysis. Eur J Gastroenterol Hepatol. 2018 Aug;30(8):819-826. doi: 10.1097/MEG.0000000000001175. Review.</citation>
    <PMID>29847488</PMID>
  </reference>
  <reference>
    <citation>Hassan C, Fuccio L, Bruno M, Pagano N, Spada C, Carrara S, Giordanino C, Rondonotti E, Curcio G, Dulbecco P, Fabbri C, Della Casa D, Maiero S, Simone A, Iacopini F, Feliciangeli G, Manes G, Rinaldi A, Zullo A, Rogai F, Repici A. A predictive model identifies patients most likely to have inadequate bowel preparation for colonoscopy. Clin Gastroenterol Hepatol. 2012 May;10(5):501-6. doi: 10.1016/j.cgh.2011.12.037. Epub 2012 Jan 10.</citation>
    <PMID>22239959</PMID>
  </reference>
  <reference>
    <citation>The Paris endoscopic classification of superficial neoplastic lesions: esophagus, stomach, and colon: November 30 to December 1, 2002. Gastrointest Endosc. 2003 Dec;58(6 Suppl):S3-43. Review.</citation>
    <PMID>14652541</PMID>
  </reference>
  <reference>
    <citation>Kang X, Zhao L, Zhu Z, Leung F, Wang L, Wang X, Luo H, Zhang L, Dong T, Li P, Chen Z, Ren G, Jia H, Guo X, Pan Y, Guo X, Fan D. Same-Day Single Dose of 2 Liter Polyethylene Glycol is Not Inferior to The Standard Bowel Preparation Regimen in Low-Risk Patients: A Randomized, Controlled Trial. Am J Gastroenterol. 2018 Apr;113(4):601-610. doi: 10.1038/ajg.2018.25. Epub 2018 Mar 13.</citation>
    <PMID>29533397</PMID>
  </reference>
  <reference>
    <citation>Kump P, Hassan C, Spada C, Brownstone E, Datz C, Haefner M, Renner F, Schoefl R, Schreiber F. Efficacy and safety of a new low-volume PEG with citrate and simethicone bowel preparation for colonoscopy (Clensia): a multicenter randomized observer-blind clinical trial vs. a low-volume PEG with ascorbic acid (PEG-ASC). Endosc Int Open. 2018 Aug;6(8):E907-E913. doi: 10.1055/a-0624-2266. Epub 2018 Aug 1.</citation>
    <PMID>30083580</PMID>
  </reference>
  <reference>
    <citation>Spada C, Cesaro P, Bazzoli F, Saracco GM, Cipolletta L, Buri L, Crosta C, Petruzziello L, Ceroni L, Fuccio L, Giordanino C, Elia C, Rotondano G, Bianco MA, Simeth C, Consalvo D, De Roberto G, Fiori G, Campanale M, Costamagna G. Evaluation of Clensia(®), a new low-volume PEG bowel preparation in colonoscopy: Multicentre randomized controlled trial versus 4L PEG. Dig Liver Dis. 2017 Jun;49(6):651-656. doi: 10.1016/j.dld.2017.01.167. Epub 2017 Feb 3.</citation>
    <PMID>28233684</PMID>
  </reference>
  <results_reference>
    <citation>Lee JM, Keum B, Yoo IK, Kim SH, Choi HS, Kim ES, Seo YS, Jeen YT, Chun HJ, Lee HS, Um SH, Kim CD, Kim MG, Jo SK. Polyethylene glycol plus ascorbic acid for bowel preparation in chronic kidney disease. Medicine (Baltimore). 2016 Sep;95(36):e4755. doi: 10.1097/MD.0000000000004755.</citation>
    <PMID>27603372</PMID>
  </results_reference>
  <results_reference>
    <citation>Yoshida N, Naito Y, Murakami T, Hirose R, Ogiso K, Inada Y, Dohi O, Okayama T, Kamada K, Uchiyama K, Ishikawa T, Handa O, Konishi H, Siah KT, Yagi N, Itoh Y. Safety and Efficacy of a Same-Day Low-Volume 1 L PEG Bowel Preparation in Colonoscopy for the Elderly People and People with Renal Dysfunction. Dig Dis Sci. 2016 Nov;61(11):3229-3235. Epub 2016 Aug 3.</citation>
    <PMID>27487795</PMID>
  </results_reference>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>January 11, 2021</study_first_submitted>
  <study_first_submitted_qc>January 13, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 14, 2021</study_first_posted>
  <last_update_submitted>January 13, 2021</last_update_submitted>
  <last_update_submitted_qc>January 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Bari</investigator_affiliation>
    <investigator_full_name>Alfredo Di Leo</investigator_full_name>
    <investigator_title>Full professor</investigator_title>
  </responsible_party>
  <keyword>Colonoscopy</keyword>
  <keyword>Bowel cleansing</keyword>
  <keyword>Adenoma detection</keyword>
  <keyword>Polyethylene glycol</keyword>
  <keyword>Hemodialysis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Simethicone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

